Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.8K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.8K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.5K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2).

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Effects of aerobic exercise on molecular aspects of asthma: involvement of SOCS-JAK-STAT.

Exercise immunology review·2019
Same author

Influence of inflammation and nitric oxide upon platelet aggregation following deposition of diesel exhaust particles in the airways.

British journal of pharmacology·2017
Same author

Transient receptor potential (TRP) channels in the airway: role in airway disease.

British journal of pharmacology·2013
Same author

Do the current house dust mite-driven models really mimic allergic asthma?

The European respiratory journal·2010
Same author

House dust mite induces direct airway inflammation in vivo: implications for future disease therapy?

The European respiratory journal·2009

Related Experiment Video

Updated: Mar 11, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K

Drugs Affecting TRP Channels.

M A Wortley1, M A Birrell1, M G Belvisi2

  • 1Respiratory Pharmacology Group, National Heart & Lung Institute, Imperial College, London, UK.

Handbook of Experimental Pharmacology
|November 20, 2016
PubMed
Summary
This summary is machine-generated.

Transient receptor potential (TRP) channels, like TRPV1, TRPA1, and TRPV4, are implicated in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Antagonists targeting these channels are being developed to treat these inflammatory lung conditions.

Keywords:
AsthmaCoughTRPA1TRPM8TRPV1TRPV4‘Chronic obstructive pulmonary disease’ (COPD)‘Transient receptor potential’ (TRP)

More Related Videos

Purification of Endogenous Drosophila Transient Receptor Potential Channels
08:39

Purification of Endogenous Drosophila Transient Receptor Potential Channels

Published on: December 28, 2021

2.3K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.7K

Related Experiment Videos

Last Updated: Mar 11, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K
Purification of Endogenous Drosophila Transient Receptor Potential Channels
08:39

Purification of Endogenous Drosophila Transient Receptor Potential Channels

Published on: December 28, 2021

2.3K
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
12:09

Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4

Published on: December 31, 2013

10.7K

Area of Science:

  • Respiratory Medicine
  • Molecular Pharmacology
  • Neuroscience

Background:

  • Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory airway diseases with significant unmet treatment needs, especially in severe cases.
  • Current therapies inadequately control symptoms in severe asthma and COPD, allowing disease progression and irreversible structural damage.
  • Transient receptor potential (TRP) channels are emerging as key players in airway inflammation and neuronal control.

Purpose of the Study:

  • To explore the role of specific TRP channels (TRPV1, TRPA1, TRPV4, TRPM8) in the pathogenesis of asthma and COPD.
  • To investigate how inflammation influences TRP channel activity and expression in the context of respiratory diseases.
  • To highlight the therapeutic potential of TRP channel antagonists for managing severe asthma and COPD.

Main Methods:

  • Review of existing scientific literature on TRP channel function in respiratory diseases.
  • Analysis of evidence linking inflammation to TRP channel activation and expression.
  • Discussion of ongoing drug development efforts targeting TRP channels for asthma and COPD.

Main Results:

  • TRPV1, TRPA1, and TRPV4 channels are implicated in regulating lung inflammation and autonomic nervous control.
  • Inflammation appears to increase TRP channel activators and sensitizers, leading to excessive channel activation.
  • This enhanced TRP channel activity may drive disease progression and symptoms like bronchoconstriction and cough.

Conclusions:

  • TRP channels are critically involved in maintaining and propagating inflammatory airway diseases.
  • TRP channel antagonists represent a promising therapeutic strategy for severe asthma and COPD.
  • Further research, including clinical trials with TRP channel antagonists, is needed to fully elucidate their role and efficacy.